KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).
Company Details
- Employees
- 33
- Address
- Jalan Letjend Suprapto Kavling 4 No.1, Jakarta Pusat,dki Jakarta 10510,indonesia
- Industry
- Biotechnology
- Website
- https://www.kg-biologics.com/
- HQ
- Jakarta Pusat, DKI Jakarta
Kgbio Questions
Kgbio's website is https://www.kg-biologics.com/
Kgbio's LinkedIn profile is https://id.linkedin.com/company/kg-bio
Kgbio has
33 employees.
View email and phone details for 33
employees at Kgbio.
Kgbio's industry is
Biotechnology
Kgbio's top competitors are
Pt. Pharos Indonesia,
Pt Etana Biotechnologies Indonesia,
Pt Bifarma Adiluhung,
Pt Prodia Stemcell Indonesia,
Pt Hexpharm Jaya Laboratories (A Kalbe Company),
Pt Kalbe Farma, Tbk,
Kalbio Global Medika,
Kalgen Laboratory,
Pt. Kalgen Dna,
Dexa Medica (Member Of Dexa Group).
Kgbio's categories are Biotechnology
